GlassScriptPhysician profile
Marc Steven Piper
NPI 1962722215
$3,797.61
in general payments reported to CMS, 2019-2025
21 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $173 · 2021: $738 · 2022: $1,268 · 2023: $267 · 2024: $23.76 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.49 | 2019-2025 | |
| Janssen Biotech, INC. | $784.78 | 2020-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.15 | 2019-2023 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $407.78 | 2019-2025 | Entyvio |
| Celgene Corporation | $303.71 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $135.11 | 2019-2023 | |
| Dova Pharmaceuticals | $122.50 | 2019 | |
| Boston Scientific Corporation | $122.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $107.06 | 2022-2023 | Dupixent |
| Genzyme Corporation | $94.18 | 2019-2025 | |
| Pfizer INC. | $56.26 | 2019-2022 | |
| Qol Medical, LLC | $53.64 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $41.09 | 2021-2022 | |
| Daiichi Sankyo INC. | $35.50 | 2021-2022 | |
| Braintree Laboratories, INC. | $31.84 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $29.98 | 2021 | |
| Fresenius Kabi USA, LLC | $29.87 | 2023 | |
| Nestle Healthcare Nutrition INC. | $21.89 | 2022 | |
| Ardelyx, INC. | $17.50 | 2022 | |
| Shionogi INC | $17.37 | 2019 | |
| Merck Sharp & Dohme LLC | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Piper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.